Literature DB >> 31403527

Cenegermin in Pediatric Neurotrophic Keratopathy.

Emilio Pedrotti1, Jacopo Bonetto, Tiziano Cozzini, Adriano Fasolo, Giorgio Marchini.   

Abstract

PURPOSE: We report a case of neurotrophic keratopathy (NK) arising after surgery for rhabdomyosarcoma of the jaw successfully treated with Cenegermin eye drops (Oxervate; Dompé Farmaceutici, Milan, Italy) in a 3-year-old boy.
METHODS: At the age of 1 year, the boy underwent surgery for rhabdomyosarcoma of the jaw, followed by radiotherapy. Subsequent NK was initially treated with preservative-free artificial tears, topical combination of dexamethasone 0.1% and netilmicin 0.3% (Netildex; Sifi, Catania, Italy), and moxifloxacin 0.5% (Vigamox; Alcon, Fort Worth, TX), followed by 10 cycles of a topical eye biopolymer containing a poly-carboxymethyl glucose sulfate solution (Cacicol; Theà, Clermont-Ferrand, France) and 4 amniotic membrane transplantations. Keratopathy was recalcitrant to therapy and tissue transplant. Therapy was switched to Cenegermin eye drops 6 times daily for 8 weeks.
RESULTS: Complete healing of the corneal epithelium was achieved at 3 weeks into treatment.
CONCLUSIONS: Cenegermin was effective in restoring corneal integrity in this pediatric patient with NK.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31403527     DOI: 10.1097/ICO.0000000000002112

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.

Authors:  Pedram Hamrah; Leyla Yavuz Saricay; M Cuneyt Ozmen
Journal:  Cornea       Date:  2022-02-02       Impact factor: 3.152

2.  Neurotrophic Keratitis Due to Congenital Corneal Anesthesia with Deafness, Hypotonia, Intellectual Disability, Face Abnormality and Metabolic Disorder: A New Syndrome?

Authors:  Arvydas Gelzinis; Dovile Simonaviciute; Agne Krucaite; Luca Buzzonetti; Hélène Dollfus; Reda Zemaitiene
Journal:  Medicina (Kaunas)       Date:  2022-05-13       Impact factor: 2.948

3.  Maternal serum eye drops to treat bilateral neurotrophic keratopathy in congenital corneal anesthesia: Case report and literature review.

Authors:  Giuseppe Giannaccare; Andrea Lucisano; Marco Pellegrini; Gianfranco Scuteri; Alessandra Mancini; Cristina Malaventura; Massimo Busin; Vincenzo Scorcia
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-18

4.  Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.

Authors:  Salvador García-Delpech; Patricia Udaondo; Alex Samir Fernández-Santodomingo; Damian García-Teillard
Journal:  Case Rep Ophthalmol       Date:  2022-08-31

5.  Neurotrophic keratopathy: Clinical presentation and effects of cenegermin.

Authors:  Julia Bing Bu; Adrian Gericke; Norbert Pfeiffer; Joanna Wasielica-Poslednik
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-16

6.  A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops.

Authors:  Riccardo Fausto; Roberto Ceccuzzi; Eleonora Micheletti; Riccardo Clerici; Ivano Riva; Andreas Katsanos; Francesco Oddone; Luciano Quaranta
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.